Ekman Lars 4
4 · PROTHENA CORP PUBLIC LTD CO · Filed May 15, 2026
Research Summary
AI-generated summary of this filing
Prothena (PRTA) Director Lars Ekman Receives 27,000-Share Award
What Happened Lars Ekman, a director of Prothena Corporation plc (PRTA), was granted 27,000 derivative securities on 2026-05-15. The Form 4 reports the acquisition at $0.00 — this reflects an award/grant of equity-linked instruments (not a cash purchase or an exercised option) rather than a market buy or sale.
Key Details
- Transaction date and amount: 2026-05-15 — Grant/award (code A) of 27,000 derivative shares reported at $0.00.
- Reported value: $0 cash consideration in the filing (award/grant recorded, not an exercised purchase).
- Shares owned after transaction: Not disclosed in this filing.
- Footnote: The award vests 100% on the earlier of the first anniversary of the grant or the issuer’s 2027 annual general meeting, subject to continuous service as a director (Footnote F1).
- Timeliness: Filing date equals report date (2026-05-15); no indication of a late filing.
Context This entry documents a director compensation grant rather than an open-market purchase or sale. The derivative award will vest according to the stated schedule and is not shown as exercised or sold here. Awards to directors are common as part of compensation and do not by themselves indicate an immediate insider view to buy or sell stock.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-05-15+27,000→ 27,000 totalExercise: $9.76Exp: 2036-05-15→ Ordinary Shares (27,000 underlying)
Footnotes (1)
- [F1]The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.